RxDoctor Payments Data

Peter Ro, MD

Internal Medicine · Richmond, VANPI 1740209964

Payments from drug & device makers

$7,047in general payments, 2019–2025

Across 360 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$710
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$636
  • Amgen$524
  • Johnson & Johnson$499
  • Cardiva Medical, Inc.$411
  • Abiomed$398
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,00299%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,047 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$877,602
Medicare patients
1,315
Services billed
13,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban656$609,075
XareltoRivaroxaban142$148,397
EntrestoSacubitril/Valsartan122$132,326
Repatha SureclickEvolocumab88$85,750
JardianceEmpagliflozin41$27,560
BrilintaTicagrelor30$18,745
FarxigaDapagliflozin Propanediol19$16,957
Bumetanide124$5,695
EdarbiAzilsartan Medoxomil13$5,504
Metoprolol Succinate442$5,496
Prasugrel Hcl74$5,218
ClopidogrelClopidogrel Bisulfate475$4,755
Atorvastatin Calcium373$4,017
Amiodarone Hcl58$3,624
Nebivolol Hcl51$3,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$308$609,075656 claims
Johnson & JohnsonXarelto$499$148,397142 claims
NovartisEntresto$710$132,326122 claims
AstraZenecaBrilinta, Farxiga$370$35,70249 claims
Boehringer IngelheimJardiance$249$27,56041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →